Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<div><ul><li>Meet Professor David Nutt. David Nutt, the Edmund J. Safra Professor of Neuropsychopharmacology and Director of the Centre for Psychedelic Research at Imperial College London, is a leading authority in the field, with more than 500 scientific publications, 36 books, and eight government reports covering psychedelic science and addiction.</li><li>In summer 2025, he assumed the role of Chief Scientific Officer at Solvonis Therapeutics (having previously served as a senior scientific advisor to the company) through an exclusive collaboration driven by two key pipeline opportunities. </li><li>The first advancing ketamine as a major alternative to existing addiction treatments and the second developing legal MDMA substitutes, currently in safety testing, aimed at becoming the next-generation standard of care for PTSD.</li></ul></div>

Meet Professor David Nutt. David Nutt, the Edmund J. Safra Professor of Neuropsychopharmacology and Director of the Centre for Psychedelic Research at Imperial College London, is a leading authority in the field, with more than 500 scientific publications, 36 books, and eight government reports covering psychedelic science and addiction.In summer 2025, he assumed the role of Chief Scientific Officer at Solvonis Therapeutics (having previously served as a senior scientific advisor to the company) through an exclusive collaboration driven by two key pipeline opportunities. The first advancing ketamine as a major alternative to existing addiction treatments and the second developing legal MDMA substitutes, currently in safety testing, aimed at becoming the next-generation standard of care for PTSD.

Solvonis' Approach to Resetting the Addicted Brain